Drug company fined £2.2m for abusing its dominant positionBMJ 2002; 324 doi: https://doi.org/10.1136/bmj.324.7331.188a (Published 26 January 2002) Cite this as: BMJ 2002;324:188
- Clare Dyer, legal correspondent
A UK drug company must pay a fine of £2.2m ($3m; €3.5m) for abusing its dominant market position to drive out competitors, the competition commission's appeal tribunal ruled last week.
In its first case the tribunal, set up under the Competition Act 1998, upheld a ruling last March by the director general of fair trading against Napp Pharmaceuticals, Cambridge, makers of MST Continus, a slow release morphine tablet taken by terminally ill patients with cancer. But the tribunal cut the £3.2m fine imposed by the director general to £2.2m.
The tribunal upheld orders to reduce the price of the drug, limit discounts to hospitals, and pay compensation to …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial